All comments can be sent at [email protected] Deadline of submission of comments shall be by 08 January 2021.
Attachment:->Draft for Comments – Supplement to FDA Circular No.2014-016 Implementing Guidelines AO2013-0022 on the Renewal of cGMP Clearance
FDA Advisory No.2021-1846 || Product Information Safety Alert on Specific…
FDA Advisory No.2017-063-B || Lifting the Advisory on the Notified…
FDA Advisory No.2021-1838 || Public Health Warning Against the Purchase…
FDA Advisory No.2021-1837 || Public Health Warning Against the Purchase…
Civic Drive Filinvest Corporate City
(8) 821-1177(8) 821-1176(8) 821-1220(8) 821-1162(8) 821-1159
Copyright © 2021. All Rights Reserved.